OMER — Omeros Corporation

Omeros Corporation Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: Reported a net loss of $30.9 million ($0.47 per share), compared to a net loss of $25.4 million ($0.43 per share) in Q2 2025.
• Adjusted Net Loss: Excluding noncash charges of $8.8 million related to embedded derivatives, the adjusted net loss was $22.1 million ($0.34 per share).
• Cash Position: As of September 30, 2025, Omeros had $36.1 million in cash and investments.
• Cash Burn: The cash burn for the quarter was $22 million.
• Financing: Completed a registered direct offering generating $20.3 million in net proceeds, priced at a 14% premium to market.

2. Strategic Updates and Business Highlights

• Novo Nordisk Agreement: Announced a definitive agreement for the asset purchase and license transaction of the MASP-3 antibody, sultanobar, valued at up to $2.1 billion. Omeros will receive $240 million upfront and $100 million in near-term milestones.
• Regulatory Progress: The Biologics License Application (BLA) for narsoplimab (Yartemlia) for treating transplant-associated thrombotic microangiopathy (TATMA) is under FDA review with a PDUFA date of December 26, 2025. The European marketing authorization application is also under review.
• Commercial Readiness: Preparations for the launch of Yartemlia are underway, including establishing a national ICD-10 diagnostic code and engagement with transplant centers and payors.

3. Forward Guidance and Outlook

• Future Expectations: Omeros anticipates potential cash flow positivity by 2027, contingent on the successful approval and launch of Yartemlia.
• Operating Expenses: Expected to increase in Q4 2025 due to marketing costs associated with the Yartemlia launch, while R&D expenses are projected to remain consistent with Q3 levels.
• Interest Income: Expected to slightly increase due to higher average cash balances.

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: The company is in a critical phase with the FDA review of Yartemlia, and any unforeseen issues could impact approval timelines.
• Market Competition: Omeros faces competitive pressures in the rare disease space, particularly concerning alternative therapies for TATMA.
• Financial Volatility: The presence of noncash mark-to-market adjustments related to embedded derivatives creates potential volatility in reported results.
• Debt Obligations: While the company plans to repay significant debt with proceeds from the Novo deal, it still faces upcoming obligations, including $17.1 million due in February 2026.

5. Notable Q&A Insights

• Launch Strategy: Management indicated that launch preparations for Yartemlia are well underway, with a focus on prioritized accounts and formulary processes that will occur in parallel with the launch.
• NTAP Expectations: The company is applying for a New Technology Add-On Payment (NTAP) to support hospital reimbursement for Yartemlia, with a positive decision expected following a presentation to CMS in December.
• FDA Interactions: Management refrained from discussing specific FDA labeling discussions but emphasized ongoing collaborative interactions with the agency regarding the data package for Yartemlia.
• Historical Control Data: Concerns regarding the use of historical controls in the clinical data were addressed, with management confident in the robustness of their data compared to recent CRLs faced by other companies.

This summary encapsulates the key points from Omeros Corporation's Q3 2025 earnings call, highlighting financial performance, strategic initiatives, and outlook while addressing potential risks and insights from the Q&A session.